Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer headquartered in Coral Gables, Florida, operates as a prime contractor supplying FDA-approved rare disease therapies — predominantly Firdapse (amifampridine) 10mg tablets — to the Department of Veterans Affairs through firm fixed-price delivery orders placed against the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The company competes in full-and-open procurement without set-aside designations, maintaining 100% prime award participation across its federal portfolio with no subcontractor relationships documented.

Catalyst's customer concentration is heavily concentrated within the VA system. The top five VA entities account for 88% of recent awards by count, but dollar concentration diverges sharply: the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 anchors $106.8 million (87% of combined potential value) through a single GSA Schedule contract award issued June 1, 2026, while VISN 5 leads by award count with eleven delivery orders totaling only $205 thousand combined potential value. The Defense Threat Reduction Agency represents a minor outlier at $205 thousand on a single award, but the VA dominates completely across all other customer rankings.

Catalyst's vehicle footprint rests on two IDVs: a $105.895 million GSA Federal Supply Schedule contract for Drugs, Pharmaceuticals, and Hematology Related Products (awarded June 1, 2026, expiring May 31, 2031) and a $5.5 million single-award Blanket Purchase Agreement with the Veterans Health Administration National Acquisition Center under the same FSS-61-IB vehicle (awarded July 26, 2024, expiring July 1, 2026). Nineteen task orders have been placed against the Pharmaceuticals and Drugs vehicle, with $16.1 million combined potential value. Representative delivery-order work includes a $19,549.38 order from VISN 5 for Firdapse 10mg tablets (awarded February 12, 2026), a $203,147 year-long order from VISN 20 (awarded November 1, 2023), and a $132,865.82 order from VISN 20 (awarded November 1, 2022). Performance is conducted at the contractor's Bartlett, Tennessee facility.

Activity has declined year over year from 2022 through 2025 (four awards in 2022 declining to two in both 2024 and 2025) before two new awards in 2026. The company's recent award trajectory shows a shift toward larger ceiling values concentrated in the recently established GSA Schedule contract rather than repeated small delivery orders. No recompete cliff is signaled in the source data; the BPA carrying $5.5 million expires July 1, 2026, but the newly awarded $105.895 million GSA Schedule vehicle extends through May 31, 2031, providing material contract stability. NAICS classification centers on Pharmaceutical Preparation Manufacturing (23 awards), with one award coded to Biotechnology R&D and one to Defense-Related Experimental Development.